Racial and Socioeconomic Equity of Tecovirimat Treatment during the 2022 Mpox Emergency, New York, New York, USA.
Maura K Lash, Ned H Latham, Pui Ying Chan, Mary M K Foote, Elizabeth A Garcia, Matthew F Silverstein, Marcia Wong, Mark Alexander, Karen A Alroy, Lovedeep Bajaj, Kuan Chen, James Steele Howard, Lucretia E Jones, Ellen H Lee, Julian L Watkins, Tristan D McPherson
Emerging infectious diseases 2023 NovWe assessed tecovirimat treatment equity for 3,740 mpox patients in New York, New York, USA, during the 2022 mpox emergency; 32.4% received tecovirimat. Treatment rates by race/ethnicity were 38.8% (White), 31.3% (Black/African American), 31.0% (Hispanic/Latino), and 30.1% (Asian/Pacific Islander/other). Future public health emergency responses must prioritize institutional and structural racism mitigation.
Citation
Maura K Lash, Ned H Latham, Pui Ying Chan, Mary M K Foote, Elizabeth A Garcia, Matthew F Silverstein, Marcia Wong, Mark Alexander, Karen A Alroy, Lovedeep Bajaj, Kuan Chen, James Steele Howard, Lucretia E Jones, Ellen H Lee, Julian L Watkins, Tristan D McPherson. Racial and Socioeconomic Equity of Tecovirimat Treatment during the 2022 Mpox Emergency, New York, New York, USA. Emerging infectious diseases. 2023 Nov;29(11):2353-2357
Mesh Tags
Substances
PMID: 37796277
View Full Text
